Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

CFC. FreitasARAkhil RajendraMDMarta Davidson

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows azacitidine plus venetoclax improves survival in AML, suggesting different outcomes in MLFS and CR patients.

Key Points

  • Patients achieving MLFS after azacitidine plus venetoclax have significantly lower overall survival compared to those achieving complete remission.
  • Half of evaluable patients reached composite complete remission, while those achieving MLFS had worse survival rates. The median overall survival for MLFS was 6.6 months compared to 22.5 months for CR patients.
  • Observational analysis of 132 AML patients treated with azacitidine plus venetoclax revealed important insights about treatment outcomes and mutational profiles.
  • Identifying risks for poor hematological recovery may help improve patient outcomes, highlighting the need for new treatment strategies.

Cite This Study

Freitas et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da20https://doi.org/10.1182/blood-2025-3508
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations
  2. 2Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia2025 · 33 citations
  3. 3Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience2025
  4. 4Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  5. 5High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen2025